Proactiveinvestors recommends
Additional Information
Market: TSXV
Sector: Pharmaceuticals
EPIC: MDG
Medicago
www.medicago.com/en

Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants.

Full Medicago profile here
Pdf

Medicago completes first part of phase II human trial for H5N1 Avian flu vaccine

22nd Dec 2010, 5:41 pm
Medicago completes first part of phase II human trial for H5N1 Avian flu vaccine

Biotech company Medicago (TSX: MDG) said Wednesday it has completed the first part of its phase II trial for the company's H5N1 Avian flu vaccine.

The company said it expects to present its interim phase II trial results early in the new year.

The placebo-controlled study is designed to test the safety and immunogenicity of different doses of the vaccine in approximately 255 healthy adults, between the ages of 18 to 60 years.

Medicago develops vaccines based on Virus-Like Particle (VLP) and plant-based manufacturing technologies. The company's methods have the potential to deliver a vaccine for testing in about a month's time, avoiding the quick spread of a pandemic.

In the first part of the phase II study, 135 healthy adults were administered twice with either a placebo, or the H5N1 vaccine, at varying doses to determine the optimal amount. The second part of the trial will be conducted in 2011.

Medicago said that to date, all results have shown the H5N1 vaccine is safe and well tolerated.

The company was up 4.4% at $0.47 as of 12:24pm EST on Wednesday.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.